Related Experiment Videos
Role of TSG101 in uterine cervix cancer
J D O'Boyle1, M L Proctor, K M Fong
1Department of Obstetrics and Gynecology, The Nancy B. and Jake L. Hamon Center for Therapeutic Oncology Research, University of Texas Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, Texas 75235, USA.
Objective:
TSG101 was first described as a possible tumor suppressor gene in breast cancer. To determine whether TSG101 might play a role in cervical carcinogenesis, we examined a panel of cervical cancer cell lines and primary tumor specimens for transcript abnormalities and mutations in TSG101.
Methods:
Total RNA was derived from cell line cultures or primary tumor specimens. We performed nested reverse transcription polymerase chain reaction (RT-PCR) with eight overlapping primer sets, followed by single-strand conformational polymorphism (SSCP) analysis, to screen for mutations in the TSG101 open reading frame. Representative normal and shifted SSCP bands were sequenced. To identify abnormal-sized transcripts, we performed RT-PCR with primers flanking the open reading frame followed by gel electrophoresis.
Results:
Mutational analysis was performed on cDNAs from 20 primary cervical tumors and 8 cervical carcinoma cell lines. Two polymorphisms were identified, neither of which resulted in an altered amino acid sequence. Transcript analysis was performed on a subset of 16 primary cervix tumors and 6 cervix carcinoma cell lines. The wild-type transcript (1228 bp) was the dominant transcript expressed in all samples. A transcript measuring 330 bp was detected in 5 of 6 cell lines and 11 of 16 primary tumor specimens.
Conclusion:
Our results suggest that mutations in TSG101 rarely occur in carcinomas of the uterine cervix. However, the presence of minor aberrant TSG101 transcripts is a common feature. The relationship between aberrant transcription and carcinogenesis should be further investigated.
Insights
Tumor suppressor gene 101 (TSG101) mutations are rare in cervical cancer. However, aberrant TSG101 transcripts are common, suggesting a potential role in cervical carcinogenesis that warrants further study.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- TSG101 was initially identified as a potential tumor suppressor gene in breast cancer.
- Its role in cervical carcinogenesis remained largely uninvestigated prior to this study.
Purpose of the Study:
- To investigate the potential involvement of TSG101 in cervical cancer development.
- This involved analyzing cervical cancer cell lines and primary tumors for mutations and transcript abnormalities in TSG101.
Main Methods:
- RNA extraction from cervical cancer cell lines and primary tumors.
- Mutation screening using nested reverse transcription polymerase chain reaction (RT-PCR) and single-strand conformational polymorphism (SSCP) analysis.
- Transcript size analysis via RT-PCR and gel electrophoresis.
Main Results:
- No significant mutations altering the amino acid sequence of TSG101 were found in cervical tumors or cell lines.
- A wild-type TSG101 transcript (1228 bp) was predominantly expressed in all samples.
- A shorter, aberrant transcript (330 bp) was detected in a majority of the analyzed cell lines and primary cervical tumors.
Conclusions:
- Mutations in TSG101 are uncommon in cervical cancer.
- The frequent detection of aberrant TSG101 transcripts suggests a potential role in cervical carcinogenesis.
- Further research is needed to elucidate the functional significance of these aberrant transcripts in cancer development.